Verastem Discontinues RAMP 203 Trial, Shifts Focus to VS-7375
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Source: Benzinga
- Trial Termination: Verastem Oncology announced the discontinuation of the RAMP 203 trial due to increased competition and higher response benchmarks, halting patient enrollment while allowing current patients to continue treatment at the investigator's discretion, highlighting the challenging market environment.
- Resource Reallocation: The company will redirect resources to VS-7375, an oral KRAS G12D inhibitor that has demonstrated a 69% response rate in 16 patients, indicating its potential in advanced non-small cell lung cancer and other solid tumors.
- Strategic Potential: Management cited stronger strategic potential for VS-7375 in an SEC filing, particularly with ongoing progress in RAMP 205, which evaluates the combination of avutometinib and defactinib with chemotherapy.
- Market Reaction: Following the announcement, Verastem's stock fell 4.34% to $7.75, reflecting investor concerns about the company's future prospects, which may impact its financing and R&D capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VSTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VSTM
Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.60 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.230
Low
14.00
Averages
15.60
High
20.00
Current: 6.230
Low
14.00
Averages
15.60
High
20.00
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verastem Discontinues RAMP 203 Trial, Shifts Focus to VS-7375
- Trial Termination: Verastem Oncology announced the discontinuation of the RAMP 203 trial due to increased competition and higher response benchmarks, halting patient enrollment while allowing current patients to continue treatment at the investigator's discretion, highlighting the challenging market environment.
- Resource Reallocation: The company will redirect resources to VS-7375, an oral KRAS G12D inhibitor that has demonstrated a 69% response rate in 16 patients, indicating its potential in advanced non-small cell lung cancer and other solid tumors.
- Strategic Potential: Management cited stronger strategic potential for VS-7375 in an SEC filing, particularly with ongoing progress in RAMP 205, which evaluates the combination of avutometinib and defactinib with chemotherapy.
- Market Reaction: Following the announcement, Verastem's stock fell 4.34% to $7.75, reflecting investor concerns about the company's future prospects, which may impact its financing and R&D capabilities.
Continue Reading
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
Continue Reading